ClinicalTrials.gg

Program

Pan-KRAS Inhibitor AMG 410

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Amgen.

Furthest: phase 1, since Jul 23, 20251 company-led study, 1 open or runningNext primary completion: Apr 18, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen11 open or runningphase 1since Jul 23, 2025Jul 23, 2025Apr 18, 2028phase 1 · NCT07094113

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07094113 · 434 planned · United States, Australia, Belgium and more

Ahead

  1. Apr 18, 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07094113

TargetBeta

KRAS →read by rule
“An orally bioavailable, macrocyclic, non-covalent inhibitor of both the active, guanosine triphosphate (GTP)-bound (ON) form and the inactive, guanosine diphosphate (GDP)-bound (OFF) form of multiple oncogenic KRAS substitution mutations, including KRAS G12D, G12V, G12C, and G13D, as well as wild-ty”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07094113Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more1RecruitingApr 18, 2028434

How it is read

Names in the registry

  • “AMG 410”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.